Fresenius Medical Care AG & Co. Stock Rating Upgraded by Societe Generale (FMS)
A number of other analysts have also recently weighed in on FMS. Analysts at Zacks upgraded shares of Fresenius Medical Care AG & Co. from an “underperform” rating to a “neutral” rating in a research note on Monday, August 4th. They now have a $34.90 price target on the stock. Separately, analysts at Piper Jaffray raised their price target on shares of Fresenius Medical Care AG & Co. from $33.00 to $34.00 in a research note on Friday, August 1st. Finally, analysts at Jefferies Group downgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to an “underperform” rating in a research note on Monday, June 30th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $37.63.
Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.64% on Monday, hitting $34.68. 108,874 shares of the company’s stock traded hands. Fresenius Medical Care AG & Co. has a 1-year low of $31.28 and a 1-year high of $37.01. The stock’s 50-day moving average is $33.79 and its 200-day moving average is $34.00. The company has a market cap of $20.968 billion and a P/E ratio of 19.63.
Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.39 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.41 by $0.02. On average, analysts predict that Fresenius Medical Care AG & Co. will post $1.70 earnings per share for the current fiscal year.
Fresenius Medical Care AG & Co KGaA is a Germany-based kidney dialysis company that operates in the fields of dialysis care and dialysis products for the treatment of end-stage renal disease (NYSE:FMS).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.